S. Ramalingam

发表

Impact of genetic polymorphisms in DNA repair enzymes on drug resistance in lung cancer.

N. Price, S. Ramalingam, V. Jain, 2004, Clinical lung cancer.

Docetaxel plus cisplatin in non-small-cell lung cancer

V. Georgoulias, S. Ramalingam, G. Simon, 2004 .

Meaningful survival in lung cancer patients.

S. Ramalingam, C. Belani, 2002, Seminars in oncology.

Cediranib (AZD2171) for the treatment of recurrent small cell lung cancer (SCLC): A California Consortium phase II study (NCI # 7097)

R. Govindan, D. Gandara, E. Vokes, 2008 .

Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study.

O. Nativ, E. Zuhowski, M. Egorin, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intravesical G emcitabine T herapy f or S uperficial T ransitional Cell C arcinoma o f t he B ladder: A P hase I a nd Pharmacokinetic S tudy

O. Nativ, E. Zuhowski, M. Egorin, 2003 .

A Review of Concurrent Chemo/Radiation, Immunotherapy, Radiation Planning, and Biomarkers for Locally Advanced Non-small Cell Lung Cancer and Their Role in the Development of ECOG-ACRIN EA5181.

C. Lovly, M. Harkenrider, N. Pennell, 2022, Clinical lung cancer.

Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies

M. Fakih, M. Egorin, S. Strychor, 2005, Cancer Chemotherapy and Pharmacology.

Age and body composition related-effects on the pharmacokinetic disposition of STEALTH liposomal CKD- 602 (S-CKD602) in patients with advanced solid tumors

S. Strychor, S. Ramalingam, W. Zamboni, 2007 .

Y. Bang, S. Strychor, S. Ramalingam, 2007 .

10th World Conference on Lung Cancer, Vancouver, British Columbia, Canada

S. Ramalingam, C. Belani, David J. Lee, 2003 .

Basic treatment considerations: chemotherapy.

S. Ramalingam, C. Belani, 2004, Hematology/oncology clinics of North America.

Phase I Pharmacokinetic-Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin (17AAG, NSC 330507), a Novel Inhibitor of Heat Shock Protein 90, in Patients with Refractory Advanced Cancers

E. Zuhowski, M. Egorin, D. Trump, 2005, Clinical Cancer Research.

2003 Highlights From: 10th World Conference on Lung Cancer Vancouver, British Columbia, Canada August 10-14, 2003

S. Ramalingam, C. Belani, David J. Lee, 2003 .

Phase I study (twice weekly schedule) of 17-allylamino-17 demethoxygeldanamycin (17AAG, NSC-704057) in patients with advanced refractory tumors

E. Zuhowski, M. Egorin, G. Chatta, 2005 .

Results of clinical trials for locally advanced and metastatic nonsmall-cell lung cancer.

S. Ramalingam, C. Belani, 2003, Seminars in thoracic and cardiovascular surgery.

Paclitaxel for non-small cell lung cancer

S. Ramalingam, C. Belani, 2004, Expert opinion on pharmacotherapy.

Taxanes for advanced non-small cell lung cancer

S. Ramalingam, C. Belani, 2002, Expert opinion on pharmacotherapy.

Docetaxel in advanced non-small cell lung cancer

H. Wakelee, S. Ramalingam, C. Belani, 2005, Expert review of anticancer therapy.

Biliary Excretion of Imatinib Mesylate and Its Metabolite CGP 74588 in Humans

M. Egorin, S. Ramalingam, R. Ramanathan, 2004, Pharmacotherapy.

Cyclooxygenase-2 inhibitors in lung cancer.

S. Ramalingam, C. Belani, 2004, Clinical lung cancer.

State-of-the-art chemotherapy for advanced non-small cell lung cancer.

S. Ramalingam, C. Belani, 2004, Seminars in oncology.

Carboplatin and docetaxel in advanced non-small-cell lung cancer: results of a multicenter phase II study

S. Ramalingam, A. Einzig, C. Belani, 2004, Cancer Chemotherapy and Pharmacology.

Carboplatin/gemcitabine combination in advanced NSCLC.

S. Ramalingam, C. Belani, 2004, Oncology.

Phase I and pharmacokinetic (PK) study of STEALTH liposomal CKD-602 (S-CKD602) in patients with advanced solid tumors

S. Strychor, S. Ramalingam, W. Zamboni, 2005 .

Early clinical data with small-molecule vascular endothelial growth factor tyrosine kinase receptor inhibitors.

G. Reddy, S. Ramalingam, V. Jain, 2004, Clinical lung cancer.

Total blockade of the epidermal growth factor receptor with the combination of cetuximab and gefitinib: A phase I study for patients with recurrent non-small cell lung cancer (NSCLC).

S. Ramalingam, C. Belani, S. Mayfield, 2006, Journal of Clinical Oncology.

Phase I study of vorinostat, a histone deacetylase (HDAC) inhibitor, in combination with carboplatin (Cb) and paclitaxel (P) for patients with advanced solid malignancies (NCI #6922).

S. Ramalingam, A. Argiris, M. Egorin, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer.

S. Ramalingam, S. Ramalingam, Yan Lin, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Growth inhibition and induction of apoptosis by fenretinide in small-cell lung cancer cell lines.

S. Ramalingam, S. Gadgeel, M. Mabry, 1995, Journal of the National Cancer Institute.

Analysis of renal function in patients entered onto CTEP-sponsored phase I studies since 1979

M. Egorin, S. Ramalingam, S. Ivy, 2007 .

Multicenter phase II study of cetuximab (C) with concomitant radiotherapy (RT) followed by consolidation chemotherapy (CT) in locally advanced non-small cell lung cancer (NSCLC).

D. Heron, J. Luketich, S. Dacic, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lung cancer in young patients: analysis of a Surveillance, Epidemiology, and End Results database.

S. Ramalingam, S. Gadgeel, G. Kalemkerian, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

2003 Highlights From: 10th World Conference on Lung Cancer Vancouver, British Columbia, Canada August 10-14, 2003

S. Ramalingam, C. Belani, David J. Lee, 2003, Clinical Lung Cancer.

Pharmacokinetic Study of Pegylated Liposomal CKD‐602 (S‐CKD602) in Patients With Advanced Malignancies

S. Ramalingam, S. Strychor, S. Ramalingam, 2009, Clinical pharmacology and therapeutics.